Introduction and Objective: Black and African American (BAA) women have a high burden of type 2 diabetes (T2D) and diabetes distress (DD). We tested the efficacy of a culturally-tailored Diabetes Tune-Up Group intervention delivered in-person or by synchronous video call (VC) to BAA women with DD and T2D.Methods: 63 BAA women were enrolled in a waitlist-controlled repeated measures trial. Data collected at enrollment (T1), baseline (T2), post-intervention (T3) and 3-month follow-up (T4) included: demographics, Diabetes Distress Scale-17 (DDS-17), depressive symptoms (PHQ-9), diabetes self-efficacy (CIDS), quality of life (SF-12) and A1c. 50 women (79% retention rate) completed measures (reported below) at all time points.Results: At enrollment, participants’ mean (M) age was 62.6 years (S.D. = 11.3), 98% Black/African American, 71% single, 33.4 (S.D. = 6.9) mean BMI with a median annual household income of $21,000- $40,000. Mean A1c was 7.86% (S.D. = 1.35%). Treatment regimen: oral hypoglycemic agents (50%), combination therapy (35.2%), and diet and exercise alone (6.2%). A Freestyle Libre 2.0 or 3.0 CGM was provided at each assessment timepoint and throughout the intervention. As predicted, no changes were observed from T1 to T2 (waitlist period) in A1c, total DDS-17 or PHQ-9 (all p’s = N.S.). Across the whole sample (in person and VC), significant changes from T2 to T4 (pre-intervention – 3-month follow-up) were observed in total DDS-17 (M = 2.54 (S.D. = 0.81) to M = 1.97 (S.D = 0.85), t = -4.94, p<.001), PHQ-9 (M = 5.56 (S.D. = 4.09) to M = 3.23 (S.D. = 3.44), t = -5.31, p<.001), CIDS (t = 4.43, p<.001) and PCS-12 (t = 4.46, p<.001). A1c showed a non-significant improvement. Primary and secondary outcomes did not differ by treatment modality (in-person vs. VC) after accounting for covariates (age, income, duration of diabetes and changes in medications; all p’s=NS).Conclusion: The Diabetes Tune Up Group is an efficacious intervention to treat diabetes distress for BAA women with T2D delivered in-person or by VC. Findings support potential scalability of VC delivery.
M. de Groot: None. K. Pinner: None. R. Klingensmith: None. B.A. Myers: None. L.E. Baker: None. B. Merchant: None. K. Haynes: None. J.S. Alwine: Stock/Shareholder; Current; Arrowhead Pharmaceuticals, Inc. Z. Yang: None. G. Bakoyannis: None.
American Diabetes Association (4-22-ICTSHD-44)
Source link
Leave a Reply